To define clinical features and SLE-associated immune pathways linked to anti-DNase1L3 antibodies in patients with SLE, we studied a prospective observational cohort for which extensive clinical and serologic variables are available, as well as whole-blood gene expression data33. This evidence concerns the gene DNASE1L3 and systemic lupus erythematosus.